Purine nucleoside phosphorylase gene therapy - PNP Therapeutics

Drug Profile

Purine nucleoside phosphorylase gene therapy - PNP Therapeutics

Alternative Names: Ad/PNP; Adenovirus/PNP; Gedeptin

Latest Information Update: 07 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Southern Research Institute; University of Alabama
  • Developer PNP Therapeutics
  • Class Gene therapies
  • Mechanism of Action DNA synthesis inhibitors; Gene transference; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pharyngeal neoplasms; Orofacial cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Phase Unknown Pharyngeal neoplasms

Most Recent Events

  • 26 Apr 2016 Phase-I development is ongoing in USA
  • 16 Jun 2015 Purine nucleoside phosphorylase gene therapy - PNP Therapeutics is available for licensing as of 16 Jun 2015. http://www.pnptherapeutics.com/
  • 08 Jun 2015 Purine nucleoside phosphorylase gene therapy - PNP Therapeutics receives Orphan Drug status for Oral and Pharyngeal neoplasms in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top